SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The September 2022 quarter revenue stood at Rs. 2656.38 millions, up 22.43% as compared to Rs. 2169.67 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2022 is Rs. -754.63 millions as compared to Net Loss of Rs. -214.33 millions of corresponding quarter ended September 2021 Operating profit Margin for the quarter ended September 2022 further decreased to -203.51% as compared to -51.12% of corresponding quarter ended September 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 2656.38 2169.67 22.43 5104.19 4177.70 22.18 9429.27 11239.73 -16.11
Other Income 107.80 53.41 101.83 226.25 179.01 26.39 420.68 473.71 -11.19
PBIDT -203.51 -51.12 298.10 -193.92 -212.49 -8.74 -14.87 1428.38 -101.04
Interest 30.21 10.29 193.59 46.88 11.68 301.37 20.74 13.01 59.42
PBDT -283.94 -61.41 362.37 -291.02 -224.17 29.82 -35.61 1415.37 -102.52
Depreciation 264.57 204.49 29.38 490.27 405.56 20.89 831.88 758.92 9.61
PBT -548.51 -265.90 106.28 -781.29 -629.73 24.07 -867.49 656.45 -232.15
TAX 206.12 -51.57 -499.69 206.12 -137.11 -250.33 -313.18 115.63 -370.85
Deferred Tax 206.12 -51.57 -499.69 206.12 -139.48 -247.78 -315.55 109.43 -388.36
PAT -754.63 -214.33 252.09 -987.41 -492.62 100.44 -554.31 540.82 -202.49
Equity 140.81 140.81 0.00 140.81 140.81 0.00 140.81 140.81 0.00
PBIDTM(%) -7.66 -2.36 225.16 -3.80 -5.09 -25.31 -0.16 12.71 -101.24

Unichem Lab Share Price

350.85 4.85 (1.40%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×